Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety Assessment of Repeated Administration of a Fully Human Monoclonal Antibody of RNAKL (TK006) in Patients With Breast Cancer-related Bone Metastases

NCT03487055 is registered in ClinicalTrials.gov with Jiangsu T-Mab Biopharma Co.,Ltd as lead sponsor.

NCT NCT03487055
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03487055 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety Assessment of Repeated Administration of a Fully Human Monoclonal Antibody of RNAKL (TK006) in Patients With Breast Cancer-related Bone Metastases
Lead sponsor
Jiangsu T-Mab Biopharma Co.,Ltd
Phase
Phase 1
Overall status
Unknown status
Start date
May 31, 2018
Completion date
May 31, 2019
Enrollment
30 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer